Aquestive Therapeutics, Inc. (AQST) stock
AQSTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.70−0.06 (-1.60%)
Close on Nov 17, 2026Market cap $464.39MP/E –Yield –
Aquestive Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Aquestive Therapeutics's profit margin for the twelve months ending Jun 30, 2026 was -144.6%. For fiscal 2025 it was -188.1%, against -76.7% the year before. The highest annual figure on record is -13.4% in fiscal 2017.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -188.1% | −111.4 |
| FY2024 | Dec 31, 2024 | -76.7% | −61.1 |
| FY2023 | Dec 31, 2023 | -15.6% | +98.6 |
| FY2022 | Dec 31, 2022 | -114.1% | +24.7 |
| FY2021 | Dec 31, 2021 | -138.8% | −17.1 |
| FY2020 | Dec 31, 2020 | -121.7% | +4.3 |
| FY2019 | Dec 31, 2019 | -125.9% | −34.9 |
| FY2018 | Dec 31, 2018 | -91.0% | −77.7 |
| FY2017 | Dec 31, 2017 | -13.4% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -165.5% | −30.0 |
| Q1 FY2026 | Mar 31, 2026 | -55.8% | +207.2 |
| Q4 FY2025 | Dec 31, 2025 | -244.8% | −101.1 |
| Q3 FY2025 | Sep 30, 2025 | -120.6% | −35.6 |
| Q2 FY2025 | Jun 30, 2025 | -135.4% | −121.8 |
| Q1 FY2025 | Mar 31, 2025 | -263.0% | −156.5 |
| Q4 FY2024 | Dec 31, 2024 | -143.7% | −82.3 |
| Q3 FY2024 | Sep 30, 2024 | -85.0% | −69.3 |
| Q2 FY2024 | Jun 30, 2024 | -13.7% | +30.1 |
| Q1 FY2024 | Mar 31, 2024 | -106.4% | −178.9 |
| Q4 FY2023 | Dec 31, 2023 | -61.4% | +54.2 |
| Q3 FY2023 | Sep 30, 2023 | -15.7% | +93.7 |
| Q2 FY2023 | Jun 30, 2023 | -43.7% | +79.2 |
| Q1 FY2023 | Mar 31, 2023 | 72.5% | +180.2 |
| Q4 FY2022 | Dec 31, 2022 | -115.6% | +145.6 |
| Q3 FY2022 | Sep 30, 2022 | -109.4% | +0.2 |
| Q2 FY2022 | Jun 30, 2022 | -122.9% | −42.3 |
| Q1 FY2022 | Mar 31, 2022 | -107.7% | +24.2 |
| Q4 FY2021 | Dec 31, 2021 | -261.3% | +23.6 |
| Q3 FY2021 | Sep 30, 2021 | -109.5% | +90.8 |
| Q2 FY2021 | Jun 30, 2021 | -80.6% | −69.8 |
| Q1 FY2021 | Mar 31, 2021 | -131.9% | +56.7 |
| Q4 FY2020 | Dec 31, 2020 | -284.9% | −207.9 |
| Q3 FY2020 | Sep 30, 2020 | -200.4% | −52.1 |
| Q2 FY2020 | Jun 30, 2020 | -10.8% | +173.2 |
| Q1 FY2020 | Mar 31, 2020 | -188.6% | −72.1 |
| Q4 FY2019 | Dec 31, 2019 | -77.0% | +5.9 |
| Q3 FY2019 | Sep 30, 2019 | -148.3% | −165.8 |
| Q2 FY2019 | Jun 30, 2019 | -184.0% | −101.6 |
| Q1 FY2019 | Mar 31, 2019 | -116.5% | −147.6 |
| Q4 FY2018 | Dec 31, 2018 | -82.9% | −30.0 |
| Q1 FY2018 | Mar 31, 2018 | 17.5% | +26.4 |
| Q4 FY2017 | Dec 31, 2017 | -82.3% | – |
| Q3 FY2017 | Sep 30, 2017 | 31.1% | – |
| Q2 FY2017 | Jun 30, 2017 | -52.9% | – |
| Q1 FY2017 | Mar 31, 2017 | -8.9% | – |
See a number that looks wrong?